IBERDO / ANNUAL
No resting orders on this market.
Important information: This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Iberdomide is an experimental oral pill developed by Bristol Myers Squibb (under the Celgene banner) to treat multiple myeloma, a cancer of the blood's plasma cells. Think of it as a precision "molecular crowbar" — it hijacks the cell's own waste-disposal machinery to break down specific proteins that cancer cells depend on to survive and multiply. By forcing the destruction of those proteins, iberdomide aims to slow or stop the growth of myeloma cells.
Resolves Yes if the FDA's decision on Iberdomide by BMS/Celgene in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Iberdomide is an experimental oral pill developed by Bristol Myers Squibb (under the Celgene banner) to treat multiple myeloma, a cancer of the blood's plasma cells. Think of it as a precision "molecular crowbar" — it hijacks the cell's own waste-disposal machinery to break down specific proteins that cancer cells depend on to survive and multiply. By forcing the destruction of those proteins, iberdomide aims to slow or stop the growth of myeloma cells.